Combination treatment with Ygalo (melflufen) continues to be safe and effective in difficult-to-treat patients with relapsed or refractory multiple myeloma (RRMM), according…
First-line maintenance therapy with Ninlaro (ixazomib) prolongs the time without disease progression in adults with multiple myeloma not treated with an autologous…
Taking Xpovio (selinexor) in combination with the steroid dexamethasone leads to promising responses in heavily treated patients with relapsed or refractory…
Ultimately aiming to advance precision medicine, the Multiple Myeloma Research Foundation (MMRF) has officially launched its Direct-to-Patient (DTP) Registry, allowing people with…
Aplidin (plitidepsin) in combination with dexamethasone significantly prolonged the survival and time to disease progression or death in heavily treated patients with…
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Velcade (bortezomib), thalidomide and dexamethasone…
Adding Darzalex (daratumumab) to a combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone — called the VRd combo — increases…
Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data…
The addition of Keytruda (pembrolizumab) to standard therapy — Revlimid (lenalidomide) or Pomalyst (pomalidomide) in combination with dexamethasone…
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to CT053, one of CARsgen Therapeutics’ lead CAR…